NASDAQ:LABT Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis $0.28 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.28 0.00 (-0.85%) As of 11/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About Lakewood-Amedex Biotherapeutics Stock (NASDAQ:LABT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LABT alerts:Sign Up Key Stats Today's Range$0.24▼$0.3450-Day Range$0.19▼$2.3252-Week Range$0.17▼$98.20Volume1.71 million shsAverage Volume44.66 million shsMarket Capitalization$669.29 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Lakewood-Amedex Biotherapeutics, Inc. is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens. The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections. Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited. The company should therefore be regarded primarily as a development-stage biotechnology enterprise.AI Generated. May Contain Errors. Read More Lakewood-Amedex Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreLABT MarketRank™: 0.50818373812 of 5 starsLakewood-Amedex Biotherapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingLakewood-Amedex Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLakewood-Amedex Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Lakewood-Amedex Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-96.77% Earnings GrowthEarnings for Lakewood-Amedex Biotherapeutics are expected to decrease by -96.77% in the coming year, from $4.96 to $0.16 per share. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.82% of the float of Lakewood-Amedex Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverLakewood-Amedex Biotherapeutics has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakewood-Amedex Biotherapeutics has recently increased by 69.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakewood-Amedex Biotherapeutics does not currently pay a dividend.Dividend GrowthLakewood-Amedex Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.50 News SentimentLakewood-Amedex Biotherapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lakewood-Amedex Biotherapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for LABT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Lakewood-Amedex Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakewood-Amedex Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.35% of the stock of Lakewood-Amedex Biotherapeutics is held by insiders.Percentage Held by InstitutionsLakewood-Amedex Biotherapeutics has minimal institutional ownership at this time.Read more about Lakewood-Amedex Biotherapeutics' insider trading history. Receive LABT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakewood-Amedex Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LABT Stock News HeadlinesLakewood-Amedex Biotherapeutics (NASDAQ:LABT) Cut to Strong Sell at Wall Street ZenNovember 10, 2026 | americanbankingnews.comLakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock RedemptionNovember 5, 2026 | insidermonkey.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet. | Paradigm Press (Ad)Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock RedemptionNovember 5, 2026 | prnewswire.comLakewood-Amedex Biotherapeutics consensus price target decreased by 37.50% to $7.65November 2, 2026 | msn.comHC Wainwright & Co. initiates coverage of Lakewood-Amedex Biotherapeutics with buy ratingOctober 28, 2026 | msn.comHC Wainwright Initiates Coverage on Lakewood-Amedex Biotherapeutics With Buy RatingOctober 28, 2026 | marketscreener.comMLakewood-Amedex Biotherapeutics Inc. Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity And Low Potential For Resistance At IDWeek 2026October 23, 2026 | marketscreener.comMSee More Headlines LABT Stock Analysis - Frequently Asked Questions How have LABT shares performed this year? Lakewood-Amedex Biotherapeutics' stock was trading at $73.50 on April 25, 2026. Since then, LABT shares have decreased by 99.6% and is now trading at $0.2824. When did Lakewood-Amedex Biotherapeutics' stock split? Shares of Lakewood-Amedex Biotherapeutics reverse split on the morning of Monday, June 22nd 2026.The 1-10 reverse split was announced on Wednesday, June 17th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 19th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lakewood-Amedex Biotherapeutics IPO? Lakewood-Amedex Biotherapeutics (LABT) raised $0 in an IPO on Thursday, April 23rd 2026. The company issued 4,689,177 shares at $0.00 per share. How do I buy shares of Lakewood-Amedex Biotherapeutics? Shares of LABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LABT CIK2079272 Weblakewoodamedex.com Phone(941) 225-2515FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio1.77 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,370,000Free Float2,243,000Market Cap$669.29 thousand OptionableN/A BetaN/A Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:LABT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredGlobal Industrial Powerhouse Taps Nasdaq Drone MicrocapA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredATTENTION: Elon’s silent partnerElon Musk's plan to take AI beyond Earth and put data centers into orbit is what Tim Bohen calls Mission X. Hi...Millionaire Pub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakewood-Amedex Biotherapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakewood-Amedex Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.